Phase 1 Start~month

Phase 1 Start: A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma

Indication
Recurrent Glioblastoma, IDH-Wildtype; Recurrent WHO Grade 4 Glioma; Recurrent Gliosarcoma

Other upcoming events for ATNM

Patent ExpiryPatent/Exclusivity Expiry: VENCLEXTA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 1 Start: A Phase I Trial of 225Ac-anti-CD33 and PD1-Inhibitor in Recurrent Glioblastoma — ATNM Phase 1 Start | BioSniper